Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11783366 Combination therapies

Patent 11783366 was granted and assigned to Genentech on October, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Gordon Bray

Iris Chan

Date of Patent

October 10, 2023

Patent Application Number

17444691

Date Filed

August 9, 2021

Patent Citations

US Patent 7511058 Heterocyclic inhibitors of MEK and methods of use thereof

US Patent 7144907 Heterocyclic inhibitors of MEK and methods of use thereof

US Patent 7307071 RAF-MEK-ERK pathway inhibitors to treat cancer

US Patent 7378423 Pyrimidine compound and medical use thereof

US Patent 7491829 RAF inhibitor compounds and methods

US Patent 7504509 Compounds and methods for development of Ret modulators

US Patent 8268852 Heterocyclic inhibitors of MEK and methods of use thereof

US Patent 8394795 Pyrazole [3, 4-B] pyridine Raf inhibitors

...

Patent Primary Examiner

Raymond J. Henley, III

CPC Code

Patent abstract

The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11783366 Combination therapies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.